MedGenome Acquires Majority Stake in Green Cross Genetics Lab to Expand Genomics-Led Diagnostics Across India

With this deal, MedGenome aims to integrate its end-to-end multi-omics laboratory infrastructure, equipped with in-house developed AI/ML-enabled pipelines, into Green Cross’s robust diagnostics network.

Bengaluru-based genomics-driven diagnostics and research services company, MedGenome, has acquired a majority stake in Gujarat-headquartered diagnostics player Green Cross Genetics Lab.

This partnership is aimed at strengthening MedGenome’s genomics diagnostics presence across India by combining its cutting-edge genomics capabilities with Green Cross’s established clinical diagnostics network.

Currently, Green Cross runs 17 labs and 35 collection centres across Gujarat, backed by more than three decades of clinical experience.

Reflecting his thoughts on the partnership, Vinod Patel, Promoter & Director, Green “We are excited to partner with MedGenome, a leader in genomic testing, to expand our diagnostics service offerings. Together, we will leverage our combined strengths across infrastructure, technology, distribution, and clinical expertise to deliver a more comprehensive menu of diagnostic services across India.

MedGenome, a global leader in genetic testing services, operates South Asia’s largest CAP-accredited multiomics laboratory. The company leverages AI/ML-enabled analysis pipelines to deliver data-driven genetic insights that support the diagnosis and management of complex diseases.

With this deal, MedGenome aims to integrate its end-to-end multi-omics laboratory infrastructure, equipped with in-house developed AI/ML-enabled pipelines, into Green Cross’s robust diagnostics network. The combined entity is expected to offer more clinically actionable testing services and deeper integration of genomics into mainstream diagnostics.

Commenting on the partnership, Dr Vedam Ramprasad, CEO of MedGenome, said, “This partnership will strengthen MedGenome’s market presence in Gujarat, allowing us to better serve a broader population. It reiterates our commitment to improving access to affordable omics solutions, particularly in Tier 2 and Tier 3 cities. With Green Cross’s three-decade legacy of trust and high-quality diagnostics, this partnership perfectly aligns with our mission to harness genomics for early, accurate disease detection and management.”

This acquisition follows MedGenome's earlier strategic expansion through Prognosis Laboratories and GenX Diagnostic.

Stay tuned for more such updates on Digital Health News